Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 437

1.

Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.

Lemoinne S, Pares A, Reig A, Ben Belkacem K, Kemgang Fankem AD, Gaouar F, Poupon R, Housset C, Corpechot C, Chazouillères O.

Clin Res Hepatol Gastroenterol. 2018 Aug 9. pii: S2210-7401(18)30121-9. doi: 10.1016/j.clinre.2018.06.009. [Epub ahead of print]

PMID:
30100231
2.

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.

Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R.

N Engl J Med. 2018 Jun 7;378(23):2171-2181. doi: 10.1056/NEJMoa1714519.

PMID:
29874528
3.

Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.

Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group.

Hepatology. 2018 May;67(5):1920-1930. doi: 10.1002/hep.29717. Epub 2018 Apr 6.

PMID:
29220537
4.

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.

Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Parés A, Mason A, Marschall HU, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, Böhm O, Pencek R, Jones D; Obeticholic Acid PBC Monotherapy Study Group.

Hepatology. 2018 May;67(5):1890-1902. doi: 10.1002/hep.29569. Epub 2018 Jan 29.

5.

Serum proteomic signatures as biomarkers of primary biliary cirrhosis diagnosis and prognosis.

Baudin B, Bruneel A, Poupon R, Vaubourdolle M.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):607-612.

PMID:
27707675
6.

Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis.

Dahlqvist G, Gaouar F, Carrat F, Meurisse S, Chazouillères O, Poupon R, Johanet C, Corpechot C; French network of Immunology Laboratories.

Hepatology. 2017 Jan;65(1):152-163. doi: 10.1002/hep.28859. Epub 2016 Nov 10.

PMID:
27688145
7.

ASBT inhibitors in cholangiopathies - Good for mice, good for men?

Poupon R.

J Hepatol. 2016 Mar;64(3):537-8. doi: 10.1016/j.jhep.2015.12.007. Epub 2015 Dec 19. No abstract available.

PMID:
26708144
8.

Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis.

Poupon R.

Dig Dis. 2015;33 Suppl 2:115-7. doi: 10.1159/000440758. Epub 2015 Dec 7.

PMID:
26642068
9.

Fenofibrate-induced massive regression of mutiple inflammatory hepatocellular adenoma.

Poupon R, Cazals-Hatem D, Arrivé L.

Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):e1-3. doi: 10.1016/j.clinre.2015.09.009. Epub 2015 Nov 11.

PMID:
26572747
10.

Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B.

Cardoso AC, Beaugrand M, de Ledinghen V, Douvin C, Poupon R, Trinchet JC, Ziol M, Bedossa P, Marcellin P.

Ann Hepatol. 2015 Nov-Dec;14(6):826-36. doi: 10.5604/16652681.1171762.

PMID:
26436354
11.

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Clin Res Hepatol Gastroenterol. 2015 Oct;39(5):e57-9. doi: 10.1016/j.clinre.2015.08.001. No abstract available.

12.

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Dig Liver Dis. 2015 Nov;47(11):924-6. doi: 10.1016/j.dld.2015.08.007. Epub 2015 Sep 26. No abstract available.

13.

Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Am J Gastroenterol. 2015 Nov;110(11):1536-8. doi: 10.1038/ajg.2015.312. Epub 2015 Sep 29. No abstract available.

14.

Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Clin Gastroenterol Hepatol. 2015 Nov;13(11):1867-9. doi: 10.1016/j.cgh.2015.08.025. Epub 2015 Sep 18. No abstract available.

PMID:
26386643
15.

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

J Hepatol. 2015 Nov;63(5):1285-7. doi: 10.1016/j.jhep.2015.06.031. Epub 2015 Sep 15. Review. No abstract available.

16.

Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Gastroenterology. 2015 Nov;149(6):1627-9. doi: 10.1053/j.gastro.2015.08.031. Epub 2015 Sep 15. No abstract available.

PMID:
26385706
17.

Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Gut. 2015 Nov;64(11):1671-2. doi: 10.1136/gutjnl-2015-310593. Epub 2015 Sep 14. No abstract available.

PMID:
26374822
18.

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Hepatology. 2015 Nov;62(5):1620-2. doi: 10.1002/hep.28140. Epub 2015 Sep 15. No abstract available.

PMID:
26372460
19.

Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.

Bosch A, Dumortier J, Maucort-Boulch D, Scoazec JY, Wendum D, Conti F, Morard I, Rubbia-Brandt L, Terris B, Radenne S, Abenavoli L, Poupon R, Chazouillères O, Calmus Y, Boillot O, Giostra E, Corpechot C.

J Hepatol. 2015 Dec;63(6):1449-58. doi: 10.1016/j.jhep.2015.07.038. Epub 2015 Aug 14.

PMID:
26282232
20.

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.

Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, Floreani A, Ponsioen CY, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Burroughs AK, Mason AL, Kowdley KV, Kumagi T, Harms MH, Trivedi PJ, Poupon R, Cheung A, Lleo A, Caballeria L, Hansen BE, van Buuren HR; Global PBC Study Group.

Gastroenterology. 2015 Dec;149(7):1804-1812.e4. doi: 10.1053/j.gastro.2015.07.061. Epub 2015 Aug 7.

PMID:
26261009

Supplemental Content

Loading ...
Support Center